Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Says Q2 Revenue Grew 20 Percent as Loss Swings to Profit

NEW YORK (GenomeWeb News) – Luminex today said total second-quarter revenues increased 25 percent as a net loss turned into a profit.
 
Receipts for the three months ended June 30 increased to $13 million from $10.7 million year over year. The company said it generated $5.8 million from the sale of 205 Luminex Systems in the period.
 
R&D costs increased 20 percent to $1.8 million from $1.5 million from the comparable quarter a year ago.
 
Luminex also reported a net income of $271,000 for the second quarter compared to a net loss of $363,000 last year.
 
Luminex had $24 million in cash and cash equivalents as of June 30.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more